Cantor Fitzgerald Downgrades Fulcrum Therapeutics to Neutral
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has downgraded Fulcrum Therapeutics from Overweight to Neutral, indicating a change in the analyst's outlook on the company's stock.

September 12, 2024 | 3:19 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cantor Fitzgerald has downgraded Fulcrum Therapeutics from Overweight to Neutral, suggesting a less optimistic view on the stock's performance.
The downgrade from Overweight to Neutral by a reputable analyst like Cantor Fitzgerald typically signals a less favorable outlook on the stock, which can lead to a negative short-term impact on the stock price as investors may adjust their positions based on this new rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100